In the UK, 2.6 million people suffer from heart disease and most are able to have their symptoms effectively managed with the prescription of beta-blocker drugs which stop adrenaline from making the heart work too hard.
However, a major side effect of beta-blockers is that they make the symptoms of asthma and other breathing problems worse, so that around 300,000 patients in the UK who also suffer from respiratory conditions are prevented from taking them.
Now, a team of scientists from the University’s Schools of Biomedical Sciences and Pharmacy will use the Wellcome Trust’s funding, made under the Seeding Drug Discovery initiative, to conduct a three-year study to develop a modified type of beta-blocker that will treat heart disease and angina without exacerbating any underlying respiratory problems..
If successful, the new drug could become the general medicine of choice for all heart patients because its targeted action will lead to a significant reduction in overall side effects.
Even the best currently available beta-blockers are poor at discriminating between the heart and lungs, causing the muscles in the lungs to tighten and making breathing more difficult in some patients who have a pre-existing lung complaint.
In patients suffering from asthma, in which environmental factors cause muscle contractions leading to a narrowing of the airway, taking these medicines can trigger an attack or, even if tolerated enough to be taken regularly, can stop other asthma drugs from working.
Doctors are also extremely wary in prescribing beta-blockers for patients suffering from heart disease and chronic obstructive pulmonary disease (COPD), a progressive condition which causes the destruction of lung tissue and increased mucus production, because any reduction in respiratory function that may be caused by the drugs could have a major impact on symptoms.
The Nottingham scientists have already developed a molecule that is much more effective at discriminating between the heart and lungs than current drugs. The funding will allow them to carry out further studies to improve the molecule to ensure that it is able to target the heart cells more effectively — therefore directing the therapeutic effect only to the heart and not the lungs. The aim is that the resulting drug will be long-lasting and could be taken orally.
Leading the research, Dr Jill Baker from the School of Biomedical Sciences said: “Once developed, this molecule will cause much less wheezing and shortness of breath and should be able to be given safely to the hundreds of thousands of patients with both heart and lung diseases. Furthermore, because it will have so few side effects, it has the potential to become the beta-blocker of choice for all heart patients.”
Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust, said: “We know that beta-blockers save lives in patients with heart disease, so making them safe for those unlucky enough to have a respiratory disorder as well is a clinical imperative. I applaud Jill Baker for questioning why beta-blockers should remain contraindicated for so many of her patients, and being stirred to correct this with an incisive programme of work. In the best traditions of medical research, this endeavour was born out of a problem encountered at the sharp end of clinical practice.”
A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau
On the way to developing a new active ingredient against chronic infections
21.08.2017 | Deutsches Zentrum für Infektionsforschung
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
21.08.2017 | Materials Sciences
21.08.2017 | Health and Medicine
21.08.2017 | Materials Sciences